Stock listing

NASDAQ:KYTX Kyverna Therapeutics, Inc. Stock

Home listing (NASDAQ) of Kyverna Therapeutics, Inc.

Follow Kyverna Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:KYTX

$4.26 USD -0.22 (-4.9%)

Close on Nov 20, 2026

Past year -42.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$4.18 – $4.58 USDNov 20, 2026
Volume
1.34M sharesNov 20, 2026
Market cap
$263.5M USDAt the close on Nov 20, 2026 · price × 61.84M shares outstanding
52-week range
$4.18 – $13.67 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$5.55M USDMedian day 813,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Kyverna Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:KYTX · Home$4.26 USD-0.22 (-4.9%)1,338,336$4.30$4.58$4.175$4.48Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:KYTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$4.26-0.22-4.9%$4.30$4.58$4.1751,338,336
$4.48-0.22-4.7%$4.69$4.75$4.401,046,701
$4.70-0.06-1.3%$4.83$4.83$4.575616,413
$4.76-0.29-5.7%$4.95$5.06$4.735767,375
$5.05+0.02+0.4%$5.275$5.54$4.82834,188
$5.03-0.09-1.8%$5.26$5.29$4.7651,197,801
$5.12+0.04+0.8%$5.12$5.23$5.018504,146
$5.08-0.09-1.7%$5.14$5.28$5.00472,269
$5.17+0.29+5.9%$4.93$5.24$4.80831,395
$4.88+0.27+5.9%$4.68$5.00$4.65885,550
$4.61-0.55-10.7%$5.11$5.11$4.4951,417,216
$5.160.000.0%$5.30$5.46$5.02973,918
$5.16-0.06-1.1%$5.28$5.48$5.12703,002
$5.22-0.45-7.9%$5.83$5.835$5.093822,251
$5.67-0.18-3.1%$5.74$5.87$5.55640,116
$5.85-0.04-0.7%$5.91$6.12$5.835844,506
$5.89+0.26+4.6%$5.58$5.935$5.56995,061
$5.63+0.36+6.8%$5.24$5.67$5.16916,565
$5.27-0.12-2.2%$5.35$5.40$5.18809,993
$5.39-0.34-5.9%$5.68$5.68$5.36827,200
$5.73-0.11-1.9%$5.825$5.985$5.67519,400
$5.84-0.20-3.3%$6.15$6.30$5.80829,200
$6.04+0.21+3.6%$5.83$6.20$5.80766,300
$5.83+0.16+2.8%$5.71$5.94$5.67837,500
$5.67-0.30-5.0%$5.94$6.05$5.64724,500
$5.97+0.285+5.0%$5.67$6.02$5.67779,400
$5.685-0.085-1.5%$5.76$5.845$5.611,275,700
$5.77-0.44-7.1%$6.17$6.17$5.7551,241,500
$6.21-0.18-2.8%$6.34$6.46$6.19417,100
$6.39+0.21+3.4%$6.20$6.58$6.175876,400
$6.18+0.01+0.2%$6.06$6.216$5.961,317,000
$6.17+0.01+0.2%$6.12$6.31$6.02650,300
$6.16-0.16-2.5%$6.38$6.45$6.13739,400
$6.32+0.10+1.6%$6.30$6.435$6.00813,500
$6.22-0.30-4.6%$6.62$6.754$6.171,180,600
$6.52-0.28-4.1%$6.80$6.91$6.51787,500
$6.80-0.04-0.6%$6.875$7.10$6.73746,200
$6.84+0.02+0.3%$6.83$6.95$6.75826,300
$6.82+0.01+0.1%$6.72$6.95$6.65997,000
$6.81-0.18-2.6%$6.99$7.015$6.621,502,400
$6.99-0.08-1.1%$7.80$7.92$6.6753,275,100
$7.07-0.44-5.9%$7.50$7.54$6.991,032,200
$7.51+0.39+5.5%$7.18$7.59$7.11836,500
$7.12-0.01-0.1%$7.25$7.26$6.99678,500
$7.13+0.09+1.3%$7.02$7.19$7.00960,600
$7.04+0.14+2.0%$7.11$7.18$6.96530,800
$6.90-0.06-0.9%$7.02$7.155$6.855685,700
$6.96-0.44-5.9%$7.34$7.34$6.871,070,900
$7.40+0.14+1.9%$7.25$7.49$7.21533,900
$7.26-0.09-1.2%$7.47$7.59$7.205751,500
$7.35-0.29-3.8%$7.51$7.53$7.34854,400
$7.64-0.43-5.3%$8.00$8.165$7.595918,200
$8.07-0.18-2.2%$8.17$8.21$7.97586,200
$8.25-0.10-1.2%$8.26$8.38$8.20500,800
$8.35-0.265-3.1%$8.71$8.78$8.28595,300
$8.615+0.265+3.2%$8.37$8.72$8.24599,900
$8.35-0.125-1.5%$8.27$8.42$7.601,782,300
$8.475+0.105+1.3%$8.33$8.52$8.14484,000
$8.37-0.27-3.1%$8.52$8.55$8.31524,900
$8.64+0.03+0.3%$8.58$8.787$8.45432,400
$8.61-0.23-2.6%$8.81$8.839$8.504413,800
$8.84+0.60+7.3%$8.36$8.885$8.265778,000
$8.24-0.18-2.1%$8.32$8.40$8.00565,100
$8.42+0.29+3.6%$8.24$8.58$8.19663,600
$8.13-0.74-8.3%$8.73$8.76$8.11953,900
Ticker
NASDAQ:KYTX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Kyverna Therapeutics, Inc. news

Kyverna Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
28 in the last 12 months · 69 in all · newest Nov 12, 2026 · oldest 2024
Decks
11 decks · latest October 2026

Where Kyverna Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:KYTX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:KYTXBOATSUnited StatesUSD

Valuation

Price/book 2.0× against a median of 2.0×: 5th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$117.8M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.0×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.2×
Beta vs S&P 500
2.02

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Kyverna Therapeutics, Inc. · NASDAQ:KYTXUS$263.5MUS$117.8Mn/an/an/a2.0×n/a0.2×2.02
Vicore Pharma Holding AB · OMXSTO:VICOUS$271.1MUS$182.5Mn/a467×n/a3.3×n/a0.0×n/a
Agenus Inc. · NASDAQ:AGENUS$270.1MUS$218.3M9.2×1.6×4.0×n/a22.0%n/a1.80
AgomAb Therapeutics NV · NASDAQ:AGMBUS$268.4M−US$6.88Mn/an/an/a0.9×n/a0.0×1.29
PepGen Inc. · NASDAQ:PEPGUS$261.8MUS$172.6Mn/an/an/a2.5×n/a0.1×1.11
Ocugen, Inc. · NASDAQ:OCGNUS$260.6MUS$178.1Mn/a37.3×n/an/an/an/a1.47
Altimmune, Inc. · NASDAQ:ALTUS$258.8MUS$28.73Mn/an/an/a0.6×n/a0.1×1.55
Prelude Therapeutics Incorporated · NASDAQ:PRLDUS$258.6MUS$136.2Mn/a6.3×n/a2.1×−247.1%0.1×1.48
OBI Pharma, Inc. · TPEX:4174US$258.5MUS$243.4Mn/a154×n/a5.7×n/a0.0×n/a
TransThera Sciences (Nanjing). Inc. · HKEX:2617US$257.1MUS$119.4Mn/an/an/a2.0×n/a0.0×n/a
Eikon Therapeutics, Inc. · NASDAQ:EIKNUS$256.8MUS$44.67Mn/an/an/a0.7×n/a0.7×1.91
Median of the othersUS$259.7MUS$154.4M9.2×37.3×4.0×2.0×−112.6%0.1×1.48

Forecasts

4 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
30.40 USD · Analysts' mean
EPS, year to Dec 2026
-2.71 · 5 analysts

Team and board

Officers

OfficerRole
Warner BiddleChief Executive Officer
Greg MartiniChief Financial Officer
Ritesh SrivastavaChief Legal and Compliance Officer
Anneliese JamesonSenior Vice President, Clinical and Development Operations
Dena GraysonSenior Vice President, Clinical Development and Medical Affairs
H. Talia ZhangSenior Vice President, Global Safety, Pharmacovigilance, and Benefit-Risk
Tracy RossinSenior Vice President, Corporate Affairs
Christi ShawExecutive Chairperson
Dan MaziaszChief Business Officer
Manal MorsyChief Regulatory Officer
Mayo PujolsChief Technology Officer
Nadia DacChief Commercial Officer
Naji GehchanChief Medical and Development Officer

Board

DirectorRole
Christi ShawExecutive Chairperson
Andrew MillerIndependent Director
Beth SeidenbergIndependent Director
Fred CohenIndependent Director
Ian ClarkIndependent Director
Mert AktarIndependent Director
Sravan K. EmanyIndependent Director

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · Before open−1.8%
Q2 2026Aug 11, 2026 · After close+0.4%
Q1 2026May 13, 2026+5.0%
Q4 2025Mar 26, 2026 · After close−2.9%
Q3 2025Nov 12, 2025 · After close−11.6%
Q2 2025Aug 12, 2025 · After close+14.9%
Q1 2025May 13, 2025 · After close−7.3%
Q4 2024Mar 27, 2025−20.0%
Q3 2024Nov 13, 2024 · After close−5.1%
Q2 2024Aug 12, 2024 · After close+7.2%
All 12 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · After close+2.4%
Q4 2023Mar 26, 2024 · After close−3.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck37 slidesOctober 2026
Corporate Update (September 2026)Corporate update29 slidesSep 24, 2026
Investor Presentation (September 2026)Investor deck37 slidesSeptember 2026
Jefferies Healthcare Conference 2026Conference31 slidesJune 2026
AAN 2026 Annual MeetingConference38 slidesApr 22, 2026
Technical Presentation (December 2025)Technical30 slidesDec 15, 2025
Technical Presentation (October 2025)Technical25 slidesOct 29, 2025
Investor Day (August 2025)Investor day97 slidesAug 28, 2025
Investor Presentation (January 2025)Investor deck29 slidesJan 13, 2025
Technical Presentation (November 2024)Technical17 slidesNovember 2024
All 11 decks
DeckKindSlidesDate
Investor Day (June 2024)Investor day31 slidesJun 14, 2024

Open Decks

Financings

RaiseDate
Public offering of common stock
Update: about US$100M · US$7.5 a share · J.P. Morgan +3
Dealers: J.P. Morgan (co-lead), Leerink Partners (co-lead), Morgan Stanley (co-lead), Wells Fargo Securities (co-lead)
Dec 17, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$22.00 a share on Feb 7, 2024.

Price
US$22.00 a share
Shares offered
14,500,000 shares of common stock
Offering size
US$319 million
Underwriters' option
Up to 2,175,000 more shares
Underwriters
J.P. Morgan, Morgan Stanley, Leerink Partners, Wells Fargo Securities · In the order on the cover
Shares delivered
On or about Feb 12, 2024

Steps

StepWhen
Draft sent to the SEC in confidenceOct 5, 2023
Filed publiclyJan 16, 2024
Amended twiceNewest Feb 6, 2024
Shares registered with an exchangeFeb 5, 2024
Declared effective by the SECFeb 7, 2024
Final prospectus, with the priceFeb 8, 2024

Open IPO · From the cover of the final prospectus (424B4) filed Feb 8, 2024

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021
Revenue0007.03M5.66M
Cost of revenue1.80M2.13M1.71M1.05M586.0K
Gross profit-1.80M-2.13M-1.71M7.03M5.66M
Research and development133.7M112.5M49.9M28.4M25.9M
Selling, general and administrative36.1M30.1M12.5M8.01M6.15M
Operating income-169.8M-142.6M-62.4M-29.4M-26.3M
Depreciation and amortization1.80M2.13M1.71M1.05M586.0K
EBITDA-168.0M-140.5M-60.7M-28.3M-25.8M
Interest expense489.0K142.0K187.0K65.0K3.00K
Income before tax-161.3M-127.5M-60.4M-28.9M-26.4M
Income tax00056.0K1.00K
Net income-161.3M-127.5M-60.4M-28.9M-26.4M
Earnings per share, basic-3.64-3.33-89.61-0.67-1.02
Earnings per share, diluted-3.64-3.33-89.61

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021
Cash and equivalents124.1M96.6M34.6M37.7M76.1M
Short-term investments155.2M189.4M22.9M13.6M0
Current assets283.0M290.6M60.7M53.3M77.1M
Property, plant and equipment1.55M3.35M2.33M
Total assets293.8M304.6M75.2M66.9M85.5M
Accounts payable5.31M4.62M4.36M1.45M773.0K
Current liabilities36.5M33.8M19.9M12.0M15.9M
Long-term debt24.7M
Total debt24.7M8.24M9.08M10.6M5.55M
Total liabilities61.5M38.1M26.0M140.9M131.7M
Shareholders' equity232.3M266.6M-13.1M-74.0M-46.3M
Shares outstanding60.4M43.2M1.25M43.1M25.8M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021
Cash from operations-153.7M-114.3M-52.4M-36.1M-22.2M
Capital spending-5.00K-2.21M-621.0K-768.0K-1.29M
Free cash flow-153.7M-116.5M-53.0M-36.9M-23.4M
Cash from investing40.0M-160.9M-8.79M-14.1M-1.29M
Cash from financing141.2M337.1M58.1M11.9M72.5M
Change in cash27.5M62.0M-3.08M-38.3M49.1M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 19, 2026Big-stake noticeSEC
8-K · Current reportSep 24, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2026Big-stake noticeSEC
8-K · Current reportJul 27, 2026Material contractSEC
All 190 filings
FilingDateTypeFiled with
8-K · Current reportJul 9, 2026Material contractSEC
8-K · Current reportJun 2, 2026Meeting outcomeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 20, 2026Insider tradeSEC
8-K · Current reportMay 18, 2026Management or board changeSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 6, 2026Insider tradeSEC
8-K · Current reportMay 4, 2026Current reportSEC
8-K · Current reportApr 22, 2026Current reportSEC
8-K · Current reportApr 21, 2026Current reportSEC
8-K · Current reportApr 20, 2026Current reportSEC
144 · Notice of proposed saleApr 17, 2026Other filingsSEC
144 · Notice of proposed saleApr 14, 2026Other filingsSEC
ARS · Annual report to shareholdersApr 13, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 13, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 13, 2026Meeting noticeSEC
144 · Notice of proposed saleApr 7, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 3, 2026Other filingsSEC
424B5 · ProspectusApr 2, 2026Offer documentSEC
144 · Notice of proposed saleMar 31, 2026Other filingsSEC
CORRESP · Letter to the SECMar 31, 2026Other filingsSEC
UPLOAD · Letter from the SECMar 30, 2026Other filingsSEC
S-8 · Registration statement for employee plansMar 26, 2026Offer documentSEC
S-3 · Registration statementMar 26, 2026Offer documentSEC
10-K · Annual reportMar 26, 2026Annual reportSEC
8-K · Current reportMar 26, 2026ResultsSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
8-K · Current reportFeb 24, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
3 · Initial statement of ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 6, 2026Big-stake noticeSEC
8-K · Current reportFeb 3, 2026Management or board changeSEC
4 · Change in ownershipJan 14, 2026Insider tradeSEC
8-K · Current reportJan 12, 2026ResultsSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
8-K · Current reportDec 17, 2025Material contractSEC
424B5 · ProspectusDec 17, 2025Offer documentSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
FWP · Free writing prospectusDec 17, 2025Offer documentSEC
424B5 · ProspectusDec 15, 2025Offer documentSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
8-K · Current reportDec 15, 2025Current reportSEC
8-K · Current reportDec 15, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeNov 17, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
8-K · Current reportNov 3, 2025Material contractSEC
8-K · Current reportOct 29, 2025Current reportSEC
8-K · Current reportOct 29, 2025Current reportSEC
8-K · Current reportSep 25, 2025Management or board changeSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 1, 2025Insider tradeSEC
8-K · Current reportJun 30, 2025Management or board changeSEC
8-K · Current reportJun 3, 2025Meeting outcomeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
EFFECT · Notice that a registration is effectiveApr 16, 2025Other filingsSEC
4 · Change in ownershipApr 15, 2025Insider tradeSEC
4 · Change in ownershipApr 15, 2025Insider tradeSEC
4 · Change in ownershipApr 15, 2025Insider tradeSEC
424B5 · ProspectusApr 15, 2025Offer documentSEC
ARS · Annual report to shareholdersApr 14, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 14, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 14, 2025Meeting noticeSEC
CORRESP · Letter to the SECApr 11, 2025Other filingsSEC
UPLOAD · Letter from the SECApr 1, 2025Other filingsSEC
8-K · Current reportMar 27, 2025Material contractSEC
S-8 · Registration statement for employee plansMar 27, 2025Offer documentSEC
S-3 · Registration statementMar 27, 2025Offer documentSEC
10-K · Annual reportMar 27, 2025Annual reportSEC
8-K · Current reportMar 27, 2025ResultsSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 24, 2025Insider tradeSEC
8-K · Current reportJan 21, 2025Current reportSEC
8-K · Current reportJan 13, 2025Current reportSEC
S-8 · Registration statement for employee plansNov 26, 2024Offer documentSEC
8-K · Current reportNov 26, 2024Management or board changeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
SC 13G · Big-stake noticeNov 12, 2024Big-stake noticeSEC
4 · Change in ownershipOct 24, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 24, 2024Insider tradeSEC
8-K · Current reportOct 21, 2024Management or board changeSEC
SC 13G · Big-stake noticeOct 10, 2024Big-stake noticeSEC
4 · Change in ownershipSep 18, 2024Insider tradeSEC
4 · Change in ownershipSep 18, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 18, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 18, 2024Insider tradeSEC
8-K · Current reportSep 16, 2024Management or board changeSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
8-K · Current reportAug 12, 2024ResultsSEC
8-K · Current reportJul 15, 2024Current reportSEC
UPLOAD · Letter from the SECJul 11, 2024Other filingsSEC
8-K · Current reportJun 14, 2024Current reportSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
SC 13D · Big-stake noticeMay 3, 2024Big-stake noticeSEC
10-K · Annual reportMar 26, 2024Annual reportSEC
8-K · Current reportMar 26, 2024ResultsSEC
SC 13G · Big-stake noticeFeb 22, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 20, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 14, 2024Insider tradeSEC
4 · Change in ownershipFeb 14, 2024Insider tradeSEC
4 · Change in ownershipFeb 14, 2024Insider tradeSEC
4 · Change in ownershipFeb 14, 2024Insider tradeSEC
4 · Change in ownershipFeb 14, 2024Insider tradeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2024Insider tradeSEC
SEC STAFF LETTERFeb 13, 2024Other filingsSEC
4 · Change in ownershipFeb 12, 2024Insider tradeSEC
8-K · Current reportFeb 12, 2024Current reportSEC
S-8 · Registration statement for employee plansFeb 8, 2024Offer documentSEC
424B4 · ProspectusFeb 8, 2024Offer documentSEC
CERT · Exchange's certificate of listingFeb 8, 2024Other filingsSEC
3 · Initial statement of ownershipFeb 8, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 8, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveFeb 8, 2024Other filingsSEC
3 · Initial statement of ownershipFeb 7, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 7, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 7, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 7, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 7, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 7, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 7, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 7, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 7, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 7, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 7, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 7, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 7, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 7, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 7, 2024Insider tradeSEC
S-1/A · Registration statement, amendedFeb 6, 2024Offer documentSEC
CORRESP · Letter to the SECFeb 5, 2024Other filingsSEC
CORRESP · Letter to the SECFeb 5, 2024Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeFeb 5, 2024Other filingsSEC
S-1/A · Registration statement, amendedJan 31, 2024Offer documentSEC
CORRESP · Letter to the SECJan 25, 2024Other filingsSEC
CORRESP · Letter to the SECJan 16, 2024Other filingsSEC
S-1 · Registration statementJan 16, 2024Offer documentSEC
UPLOAD · Letter from the SECJan 10, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftJan 5, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedJan 5, 2024Offer documentSEC
UPLOAD · Letter from the SECDec 28, 2023Other filingsSEC
SEC STAFF LETTERDec 15, 2023Other filingsSEC
DRSLTR · Letter to the SEC with a draftDec 13, 2023Other filingsSEC
DRS/A · Draft registration statement, amendedDec 13, 2023Offer documentSEC
UPLOAD · Letter from the SECNov 21, 2023Other filingsSEC
DRSLTR · Letter to the SEC with a draftNov 9, 2023Other filingsSEC
DRS/A · Draft registration statement, amendedNov 9, 2023Offer documentSEC
DNov 6, 2023Other filingsSEC
UPLOAD · Letter from the SECNov 1, 2023Other filingsSEC
DRS · Draft registration statementOct 4, 2023Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Kyverna Therapeutics, Inc.’s releases

Common shares
61,843,444
Fully diluted
61,843,444

Fully diluted

LineShares
Common shares61,843,444

Share count over time

CountShares
Nov 22, 202661,843,444

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
GordonMD Global Investments LP4.52M7.2%US$30.7MSep 30, 2026
Gilead Sciences, Inc.4.13M6.5%US$28.1MSep 30, 2026
AIGH Capital Management LLC3.65M5.8%US$24.8MSep 30, 2026
BlackRock3.24M5.1%US$22MSep 30, 2026
Vanguard2.67M4.2%US$18.2MSep 30, 2026
Bain Capital Life Sciences Investors, LLC1.31M2.1%US$8.92MSep 30, 2026
T. Rowe Price1.21M1.9%US$8.21MSep 30, 2026
State Street1.2M1.9%US$8.18MSep 30, 2026
Geode Capital1.05M1.7%US$7.17MSep 30, 2026
Insight Holdings Group, LLC989K1.6%US$6.73MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Millennium826K1.3%US$5.62MSep 30, 2026
Propel Bio Management, LLC701K1.1%US$4.76MSep 30, 2026
Mbb Public Markets I LLC614K0.97%US$4.18MSep 30, 2026
UBS600K0.95%US$4.08MSep 30, 2026
Morgan Stanley552K0.87%US$3.76MSep 30, 2026
Goldman Sachs552K0.87%US$3.75MSep 30, 2026
Fidelity538K0.85%US$3.66MSep 30, 2026
Adage Capital Partners Gp, L.L.C.500K0.79%US$3.4MSep 30, 2026
Wells Fargo462K0.73%US$3.14MSep 30, 2026
Woodline Partners LP423K0.67%US$2.88MSep 30, 2026
Schwab334K0.53%US$2.27MSep 30, 2026
Susquehanna329K0.52%US$2.23MSep 30, 2026
Renaissance Technologies328K0.52%US$2.23MSep 30, 2026
Northern Trust325K0.51%US$2.21MSep 30, 2026
Dimensional279K0.44%US$1.89MSep 30, 2026
BNP Paribas276K0.44%US$1.88MSep 30, 2026
Nuveen240K0.38%US$1.63MSep 30, 2026
Burkehill Global Management, LP200K0.32%US$1.36MSep 30, 2026
Point72 Asset Management, L.P.187K0.30%US$1.27MSep 30, 2026
Simplify Asset Management Inc.183K0.29%US$1.24MSep 30, 2026
D. E. Shaw & Co., Inc.147K0.23%US$999KSep 30, 2026
Wellington146K0.23%US$995KSep 30, 2026
TD146K0.23%US$996KSep 30, 2026
Stifel Financial Corp140K0.22%US$951KSep 30, 2026
Citadel137K0.22%US$932KSep 30, 2026
Barclays136K0.22%US$926KSep 30, 2026
Raymond James Financial Inc129K0.20%US$877KSep 30, 2026
BNY104K0.17%US$710KSep 30, 2026
Manufacturers Life Insurance Company, The101K0.16%US$685KSep 30, 2026
Nano Cap New Millennium Growth Fund L P90,0000.14%US$612KSep 30, 2026
Franklin Templeton77,9960.12%US$402KSep 30, 2026
Marshall Wace, LLP73,2760.12%US$498KSep 30, 2026
Invesco73,0010.12%US$496KSep 30, 2026
Man Group plc71,9180.11%US$489KSep 30, 2026
Aquatic Capital Management LLC71,8140.11%US$488KSep 30, 2026
American Century70,0620.11%US$476KSep 30, 2026
Rhumbline Advisers54,1370.09%US$368KSep 30, 2026
XTX Topco Ltd45,0600.07%US$306KSep 30, 2026
Bank of America44,9840.07%US$306KSep 30, 2026
CPP Investments44,7000.07%US$304KSep 30, 2026

This page holds 50 of 121 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.4M2.2%US$12.5MJun 30, 2026
iShares Russell 2000 ETF1.07M1.7%US$9.57MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.857K1.4%US$7.63MJun 30, 2026
Fidelity Small Cap Index Fund458K0.72%US$3.35MJul 31, 2026
Vanguard Extended Market Index Fund448K0.71%US$3.99MJun 30, 2026
iShares Russell 2000 Value ETF352K0.56%US$3.14MJun 30, 2026
iShares Biotechnology ETF266K0.42%US$2.37MJun 30, 2026
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF261K0.41%US$2.32MJun 30, 2026
Fidelity Extended Market Index Fund184K0.29%US$1.57MMay 31, 2026
Simplify Propel Opportunities ETF183K0.29%US$1.63MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Nuveen Equity Index Fund178K0.28%US$1.3MJul 31, 2026
Schwab U.S. Small-Cap ETF168K0.27%US$1.43MMay 31, 2026
Invesco Dorsey Wright SmallCap Momentum ETF166K0.26%US$1.42MMay 31, 2026
iShares Micro-Cap ETF139K0.22%US$1.24MJun 30, 2026
Ultra-Small Company Fund112K0.18%US$998KJun 30, 2026
WesMark Small Company Fund110K0.17%US$983KJun 30, 2026
Goldman Sachs Small Cap Equity Insights Fund106K0.17%US$775KJul 31, 2026
Schwab Small-Cap Index Fund102K0.16%US$748KJul 31, 2026
Fidelity Enhanced Small Cap Core ETF87,9420.14%US$784KJun 30, 2026
Master Small Cap Index Series78,4400.12%US$699KJun 30, 2026
Avantis U.S. Small Cap Equity ETF65,6200.10%US$559KMay 31, 2026
Fidelity Total Market Index Fund64,5910.10%US$550KMay 31, 2026
Nuveen Small Cap Blend Index Fund55,8070.09%US$407KJul 31, 2026
T. Rowe Price Health Sciences Portfolio55,1730.09%US$492KJun 30, 2026
Fidelity Small Cap Value Index Fund53,7210.08%US$479KJun 30, 2026
Fidelity Series Total Market Index Fund53,6640.08%US$457KMay 31, 2026
Goldman Sachs Small Cap Value Insights Fund46,8350.07%US$342KJul 31, 2026
EQ/2000 Managed Volatility Portfolio45,6560.07%US$407KJun 30, 2026
Fidelity Nasdaq Composite Index Fund37,9590.06%US$323KMay 31, 2026
iShares Russell 2000 Growth ETF34,1670.05%US$304KJun 30, 2026
U.S. Small Cap Portfolio31,2150.05%US$228KJul 31, 2026
Invesco RAFI US 1500 Small-Mid ETF30,6510.05%US$224KJul 31, 2026
LVIP State Street Small-Cap Index Fund30,6000.05%US$273KJun 30, 2026
Ultra-Small Company Market Fund29,0000.05%US$258KJun 30, 2026
Schwab Total Stock Market Index Fund25,0000.04%US$183KJul 31, 2026
Vanguard Institutional Total Stock Market Index Fund23,1480.04%US$206KJun 30, 2026
Vanguard Balanced Index Fund22,4590.04%US$200KJun 30, 2026
Small Cap Index Fund21,6840.03%US$193KJun 30, 2026
Fidelity ZERO Total Market Index Fund20,1350.03%US$147KJul 31, 2026
Global X Russell 2000 ETF19,9450.03%US$146KJul 31, 2026
Federated Hermes Managed Volatility Fund II18,0000.03%US$160KJun 30, 2026
Health Sciences Trust17,5180.03%US$156KJun 30, 2026
T. Rowe Price Extended Equity Market Index Fund16,6770.03%US$149KJun 30, 2026
ATM Small Cap Managed Volatility Portfolio16,0500.03%US$143KJun 30, 2026
Dimensional U.S. Small Cap ETF15,8730.03%US$116KJul 31, 2026
Schwab U.S. Broad Market ETF15,0000.02%US$128KMay 31, 2026
MetLife Russell 2000 Index Portfolio14,5220.02%US$129KJun 30, 2026
Fidelity ZERO Extended Market Index Fund14,1090.02%US$103KJul 31, 2026
Goldman Sachs Variable Insurance Trust Small Cap Equity Insights Fund13,9310.02%US$124KJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio13,6000.02%US$121KJun 30, 2026

This page holds 50 of 112 holders. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
Dr. Beth C. Seidenberg ("Seidenberg")7.80%4.66MDec 31, 2025Schedule 13G
GordonMD Global Investments LP7.34%4.52MSep 30, 2026Schedule 13G
Michael P. Rubin6.10%3.47MDec 31, 2025Schedule 13G
Orin Hirschman5.90%3.65MSep 30, 2026Schedule 13G
BlackRock, Inc.5.10%3.1MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Beth C Seidenberg
Other companies: Latigo Biotherapeutics, Inc. (Director · Since at least Aug 6, 2026); Sagimet Biosciences Inc. - Series A (Director · Since at least Jul 13, 2023); Vera Therapeutics, Inc. (Director · Since at least May 13, 2021); Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Progyny, Inc. (Director · Oct 24, 2019 – May 23, 2024 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); Atara Biotherapeutics, Inc. (Director · Oct 15, 2014 – May 31, 2023 · Past); Epizyme Inc (Director · May 30, 2013 – Jun 30, 2019 · Past); Tesaro Inc (Director · Jun 27, 2012 – Jan 22, 2019 · Past)
Director · Since at least Feb 7, 2024
Beth Seidenberg
Other companies: Sagimet Biosciences Inc. - Series A (Lead Independent Director · Since at least Nov 4, 2026); Vera Therapeutics, Inc. (Founding Managing Director, Westlake Village BioPartners · Since at least Nov 4, 2026); Latigo Biotherapeutics, Inc. (Founding Managing Director, Westlake BioPartners · Since at least Aug 10, 2026)
Independent Director · Since at least May 29, 2026
Sravan Emany
Other companies: Beam Therapeutics Inc. (Chief Financial Officer · Since at least Dec 19, 2024); Assertio Holdings, Inc. (Director · Since at least Nov 14, 2023); Ironwood Pharmaceuticals, Inc. (SVP, COO and CFO · Dec 6, 2021 – Nov 18, 2024 · Past)
Independent Director · Since at least Feb 24, 2026
Fred E Cohen
Other companies: CareDx, Inc. (Director · Since at least Jun 12, 2026); Intellia Therapeutics, Inc. (Director · Since at least Jun 9, 2026)
Director · Since at least May 27, 2026
Marc Grasso
Other companies: Alector, Inc. (Chief Financial Officer · Since at least Feb 7, 2022); Kura Oncology, Inc. (CFO, CBO · Aug 21, 2018 – Jan 26, 2022 · Past)
Chief Financial Officer · Since at least Jun 30, 2025
Peter Maag
Other companies: CareDx, Inc. (Director · Since at least Jul 16, 2014); Miromatrix Medical Inc (Director · Jun 23, 2021 – Dec 12, 2023 · Past)
Chief Executive Officer, Director · Feb 7, 2024 – Feb 7, 2024 · Past
Christi Shaw
Other companies: Beam Therapeutics Inc. (Board Member · Since at least Nov 5, 2026)
Executive Chairperson · Since at least Feb 24, 2026
Fred Cohen
Other companies: Intellia Therapeutics, Inc. (Independent Director · Since at least Jun 10, 2026)
Independent Director · Since at least May 29, 2026
Greg Martini
Other companies: Ironwood Pharmaceuticals, Inc. (Chief Financial Officer · Since at least May 7, 2026)
Chief Financial Officer · Since at least Aug 11, 2026
Gregory S Martini
Other companies: Ironwood Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Jan 27, 2025)
Chief Financial Officer · Since at least May 18, 2026
All 26 people
PersonSeat
Andrew MillerIndependent Director · Since at least Feb 24, 2026
Anneliese JamesonSenior Vice President, Clinical and Development Operations · Since at least Nov 4, 2026
Dan MaziaszChief Business Officer · Since at least Mar 27, 2025
Dena GraysonSenior Vice President, Clinical Development and Medical Affairs · Since at least Nov 4, 2026
H. Talia ZhangSenior Vice President, Global Safety, Pharmacovigilance, and Benefit-Risk · Since at least Nov 4, 2026
Ian ClarkIndependent Director · Since at least Jan 12, 2026
Manal MorsyChief Regulatory Officer · Since at least Nov 4, 2026
Mayobanex PujolsChief Technology Officer · Since at least Feb 9, 2026
Mayo PujolsChief Technology Officer · Since at least Jul 27, 2026
Mert AktarIndependent Director · Since at least Oct 21, 2024
Nadia DacChief Commercial Officer · Since at least Aug 11, 2026
Naji GehchanChief Medical and Development Officer · Since at least Oct 23, 2026
Ritesh SrivastavaChief Legal and Compliance Officer · Since at least Aug 11, 2026
Ryan Alexander JonesChief Financial Officer · Feb 7, 2024 – Apr 11, 2025 · Past
Tracy RossinSenior Vice President, Corporate Affairs · Since at least Mar 27, 2025
Warner BiddleChief Executive Officer · Since at least Sep 16, 2024

Open People

Log in to ask 6ix AI your own questions about Kyverna Therapeutics, Inc.